Latest News in the pharma Industry

Research & Development

Juniper and Crystec sign agreement for next-generation medicines

Juniper and Crystec sign agreement for next-generation medicines

15 Feb 2016

Read more 
Incyte decides to discontinue JANUS studies of ruxolitinib plus capecitabine

Incyte decides to discontinue JANUS studies of ruxolitinib plus capecitabine

15 Feb 2016

The decision to stop the study was made after a planned interim analysis of JANUS 1 demonstrated that ruxolitinib plus capecitabine did not show a sufficient level of efficacy to warrant continuation.

Read more 
JHL Biotech receives approval From European authorities to begin biosimilar clinical trial

JHL Biotech receives approval From European authorities to begin biosimilar clinical trial

15 Feb 2016

First biotech company in Greater China region to receive European approval.

Read more 
Newly published head-to-head data show Stiolto Respimat improved lung function across range of measures

Newly published head-to-head data show Stiolto Respimat improved lung function across range of measures

10 Feb 2016

Stiolto Respimat was compared with a European formulation of a combination of a long-acting beta agonist, salmeterol, and an inhaled corticosteroid, fluticasone propionate.

Read more 
Synlogic announces first industry collaboration with AbbVie to develop a new class of medicines designed to power the microbiome

Synlogic announces first industry collaboration with AbbVie to develop a new class of medicines designed to power the microbiome

10 Feb 2016

Multi-year R&D collaboration with AbbVie focused on novel medicines for treatment of inflammatory bowel disease.

Read more 
Biogen joins pioneering Target Validation Collaboration

Biogen joins pioneering Target Validation Collaboration

9 Feb 2016

The Centre for Therapeutic Target Validation welcomes new member Biogen, expanding its efforts to accelerate drug discovery research.

Read more 
Optibrium supports global health through academic and not-for-profit consortium

Optibrium supports global health through academic and not-for-profit consortium

9 Feb 2016

Access to StarDrop will support development of new treatments for neglected diseases via global health programme.

Read more 
FDA approves expanded use of BMS’s Daklinza

FDA approves expanded use of BMS’s Daklinza

8 Feb 2016

Updated label provides new treatment option for patients with HIV-1 coinfection, advanced cirrhosis, and post-liver transplant HCV recurrence.

Read more 
Microbix announces new product development program to help combat Zika virus

Microbix announces new product development program to help combat Zika virus

8 Feb 2016

Using its established development platform and unique expertise in virology, Microbix intends to develop and launch a range of products to help combat the Zika virus.

Read more 
Oasmia submits MAA to the EMA for its lead cancer product Apealea

Oasmia submits MAA to the EMA for its lead cancer product Apealea

8 Feb 2016

The indication sought for Apealea is treatment of epithelial ovarian cancer in combination with carboplatin.

Read more 
Affinivax secures additional funding from Gates Foundation to advance its novel pneumococcal vaccine towards clinical trials

Affinivax secures additional funding from Gates Foundation to advance its novel pneumococcal vaccine towards clinical trials

5 Feb 2016

Company achieves key milestones and additional $2.5 million from the Gates Foundation.

Read more 
Vertex receives Complete Response Letter from FDA regarding Kalydeco

Vertex receives Complete Response Letter from FDA regarding Kalydeco

5 Feb 2016

Company plans to meet with FDA to determine appropriate path forward.

Read more